Catherine Stehman-Breen
CIK 1702233 · SVP, Chief Medical Officer · last filed 2026-06-09
Catherine Stehman-Breen is a SVP, Chief Medical Officer who has filed 22 SEC Form 4 insider transactions across 4 companies since 2017. The most recent filing, for DYN, was dated Jun 9, 2026. Current disclosed insider exposure totals $1.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DYN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
301 BINNEY STREET
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DYN | Director | 115,713 | $16.04 | $1.86M | $0 | 8 | 2026-06-09 |
| TNYA | Director | — | $0.29 | — | $0 | 5 | 2026-05-29 |
| Generation Bio Co. (GBIO) Delisted | Director | 0 | $5.34 | $0 | $0 | 8 | 2026-02-09 |
| SRPT | SVP, Chief Medical Officer | — | $14.19 | — | $0 | 1 | 2017-04-05 |
Recent Filings
22 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-09 | DYN | Grant (A) | — | $0 | EDGAR |
| 2026-05-29 | TNYA | Grant (A) | — | $0 | EDGAR |
| 2026-02-09 | Generation Bio Co. (GBIO) Delisted | Mixed | −4,752 | $0 | EDGAR |
| 2025-06-06 | Generation Bio Co. (GBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-03 | DYN | Grant (A) | — | $0 | EDGAR |
| 2025-05-30 | TNYA | Grant (A) | — | $0 | EDGAR |
| 2024-10-21 | TNYA | Grant (A) | — | $0 | EDGAR |
| 2024-06-10 | Generation Bio Co. (GBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-24 | DYN | Grant (A) | — | $0 | EDGAR |
| 2023-06-12 | TNYA | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).